Brief: Coherus Presents Positive Phase 2 Clinical Data On Casdozokitug
18/01/2024 22:20
Jan 18 (Reuters) - Coherus BioSciences Inc CHRS.O :
* COHERUS PRESENTS POSITIVE PHASE 2 CLINICAL DATA ON
CASDOZOKITUG,
A FIRST-IN-CLASS IL-27-TARGETED ANTIBODY, AT THE 2024 ASCO GI
CANCERS SYMPOSIUM
Source text for Eikon: ID:nGNXc9rZrH
Further company coverage: CHRS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coherus Oncology
See all newsBrief: Coherus Oncology Initiates Process To Sell Legacy Biosim Assets
Brief: Coherus Oncology Announces Special Dividend Of Biosimilar Contingent Value Rights
Coherus Oncology Inc reports results for the quarter ended June 30 - Earnings Summary
Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates
Brief: Coherus Oncology Q2 Net Income USD -20.631 Million